Caidya

What Caidya does

Caidya is a privately held, full-service global Clinical Research Organization (CRO) headquartered in Raleigh, North Carolina, formed through the 2021 merger of dMed (founded 2016 in China by Dr. Lingshi Tan) and Clinipace (founded 2004) and rebranded under the Caidya name in 2022. The company provides end-to-end clinical development services to small- and mid-sized biotech and biopharmaceutical innovators as its primary customer segment, and to mid- and larger-sized pharmaceutical companies via Functional Service Provision (FSP) and hybrid delivery models. Service offerings span Early Phase Development, Phase II/III trials, Regulatory Strategy, Medical Affairs, Post-Marketing Surveillance, Clinical Operations, RBQM, Medical Monitoring, Data Management, Biometrics, Pharmacovigilance, and Regulatory Services, supported by specialized therapeutic expertise across 12 areas including Oncology & Hematology, Cardiovascular-Metabolic, Rare Disease, Pediatrics, Cell & Gene Therapy, and Neurology.

Caidya operates through approximately 25 offices across more than 50 countries with 1,130+ employees globally, maintaining 3,800+ Principal Investigator relationships and 2,700+ site relationships. Its distinctive cross-border execution capability is anchored by deep presence in China (offices in Chengdu, Shanghai, Beijing, Wuhan, and Hong Kong) and broader Asia-Pacific coverage, providing sponsors access to patient populations in geographies where Western CROs typically have limited reach. The company's unified Clinical Trial Technology Ecosystem integrates EDC, CTMS, safety systems, and third-party tools with AI-enabled analytics for risk detection, data reconciliation, and anomaly identification, and the company has published formal AI Principles governing its use of AI with human-in-the-loop accountability.

Revenue is generated through professional services contracts with biopharma sponsors across multiple therapeutic areas, with pricing not publicly disclosed and customized to each engagement. Documented operational outcomes include approximately 60% faster trial activation-to-close times versus industry average for oncology trials, 185 Phase III studies with 6,500+ sites and 58,000+ patients, 268 Phase I studies, 31 cell therapy studies and 31 gene therapy studies, and 39 pediatric studies with 540 sites. The company is backed by Rubicon Founders ($165M strategic growth investment, 2025), Qiming Ventures, and Vivo Capital, with board representation from each sponsor.

Name

Caidya

Legal name

Caidya

Website

https://caidya.com

Company type

Private

Founded year

2021

Operating status

Operating

Headcount range

501–1,000 employees

Short description

Caidya is a global full-service Clinical Research Organization providing end-to-end clinical development services across 12 therapeutic areas to small and mid-sized biotech and biopharmaceutical companies, with a distinctive cross-border execution capability anchored by deep China and Asia-Pacific presence across 50+ countries.

Ownership category

akta.pro rank

Product category

Contract Research Organization (CRO) Services

NAICS

Scientific Research and Development Services (5417), Professional, Scientific, and Technical Services (54)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Clinical CROs (Phase I–IV) (HLAGAAAA)

akta.pro secondary industries

Clinical Data Management, Biostatistics & Statistical Programming CROs (HLAGAAAF), Pharmacovigilance, Risk Management & Medical Affairs CROs (HLAGAAAH), Medical Writing & Regulatory Submission Support CROs (HLAGAAAG), Patient Recruitment, Site Feasibility & Trial Enablement CROs (HLAGAAAI), Specialty Therapeutic-Area CROs (e.g., oncology/rare disease) (HLAGAAAL)

Keywords

• Clinical research services
• Contract research organization
• Clinical trial management
• Biopharmaceutical development services
• Regulatory affairs services

Headquarters

HQ city

Raleigh

HQ country

United States

HQ region

North America

Offices26 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Technology or R&D, Infrastructure

Revenue model

1. Clinical Research Services: Full-service CRO providing end-to-end clinical development support including study design, project management, clinical operations, clinical data management, biostatistics, regulatory support, and medical monitoring for local, regional, and international cross-border trials. Revenue is generated through service contracts with biopharma sponsors across multiple therapeutic areas.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Core offering

Caidya is a global full-service Clinical Research Organization (CRO) providing end-to-end clinical development services to biotech and biopharma sponsors, including study design, project management, clinical operations, clinical data management, biostatistics, regulatory strategy, pharmacovigilance, and medical monitoring. Services are delivered across 50+ countries with particular strength in cross-border trials involving China and Asia-Pacific, supported by an integrated Clinical Trial Technology Ecosystem that connects EDC, CTMS, and safety systems with AI-enabled analytics.

Product overview

Caidya is a global full-service Clinical Research Organization (CRO) offering end-to-end clinical development services through an integrated platform model. The core Clinical Trial Technology Ecosystem connects EDC, CTMS, and safety systems, supporting services across two main phases: Clinical Development Strategy (Early Phase Development, Phase II/III, Regulatory Strategy, Medical Affairs, Post-Marketing Surveillance) and Clinical Trial Delivery (Clinical Operations, Study Start-Up, Trial Feasibility, Project Management, RBQM, Medical Monitoring, Clinical Data Management, Biometrics, Medical Writing, Regulatory Services, Pharmacovigilance, Quality Assurance). The company provides specialized Therapeutic Expertise across 12 therapeutic areas including Oncology & Hematology, Cardiovascular-Metabolic, Rare Disease, Pediatrics, Gastroenterology, Nephrology, Dermatology, Ophthalmology, Cell & Gene Therapy, Neurology, Immunology, and Infectious Disease. Caidya's differentiated approach emphasizes cross-border execution capability with particular strength in China and Asia-Pacific.

Differentiator

Problem solved

Functional benefit

Products and services

• Early Phase Development Strategic trial design, risk-based quality management (RBQM), and centralized monitoring for Phase I and early-phase studies to enable high-quality data and confident dose optimization decisions for biopharma sponsors.
• Phase II/III Clinical Trials Full-service approach for late-phase trials including clinical operations, medical monitoring, data management, biometrics, safety, and scalable execution across global sites for biopharma sponsors.
• Regulatory Strategy Global regulatory strategy services including early agency engagement, endpoint harmonization, diversity planning, and advanced therapy regulatory navigation across FDA, EMA, NMPA, and other authorities for biopharma sponsors.
• Medical Affairs Medical oversight, monitoring, safety governance, and submission-ready documentation services to keep global trials aligned and inspection-ready for biopharma sponsors.
• Post-Marketing Surveillance Phase IV studies, pharmacovigilance, adverse event management, risk minimization, and regulatory reporting to maintain safety compliance after product approval for biopharma sponsors.
• Clinical Operations Global clinical trial execution including monitoring, site management, and project management from study start-up through close-out for biopharma sponsors.
• Risk-Based Quality Management (RBQM) Proactive risk assessment, centralized monitoring, and quality oversight to maintain data integrity and reduce unnecessary site burden across global trials for biopharma sponsors.
• Medical Monitoring Medical oversight and safety surveillance across clinical trials with structured escalation pathways for emerging signals for biopharma sponsors.
• Clinical Data Management Integrated data management, programming, and analytics to streamline data flows and enhance quality across global trials for biopharma sponsors.
• Biometrics Clinical research biostatistics and statistical programming for trial design, analysis, and regulatory submissions for biopharma sponsors.
• Pharmacovigilance End-to-end safety services including AE/SAE case management, expedited reporting, signal detection, and safety labeling review for biopharma sponsors.
• Regulatory Services Regulatory submission support, agency interaction, and compliance coordination across global health authorities for biopharma sponsors.
• Oncology & Hematology Clinical Research Specialized clinical research services for oncology and hematology trials from dose escalation through global pivotal studies, including cell and gene therapy, for biopharma sponsors.
• Cardiovascular-Metabolic Clinical Research Cardiovascular outcomes trial (CVOT) experience, cardiac safety capabilities, and integrated delivery for cardiovascular outcomes trials and cardiometabolic/endocrine drug and device programs for biopharma sponsors.
• Rare Disease Clinical Research Patient-first approach with tailored planning and flexible execution for rare disease clinical research addressing limited patient pools and diagnostic challenges for biopharma sponsors.
• Pediatrics Clinical Research Age-appropriate trial design, caregiver-centric strategies, and regulatory alignment (PREA/BPCA) for pediatric clinical studies for biopharma sponsors.
• Cell & Gene Therapy Clinical Research End-to-end cell and gene therapy development including regulatory navigation, CMC alignment, chain of identity management, cold chain logistics, and long-term follow-up for biopharma sponsors.

Quantifiable outcome

• Trial activation-to-close times ~60% faster vs. industry average for oncology trials
• +4 more outcomes

Named customers4 records

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability6 records

Feature3 records

Partnerships

One partnership is on record.

• Clinical Trials for AllminorStrategic or Co-development Partner · 1 January 2026Caidya partners with Clinical Trials for All to increase global awareness and engagement in clinical trials, supporting patient access and participation in clinical research.

Scale indicators17 records

Recent moves16 records

Expansion highlights6 records

Broad incumbents

• IQVIA: The largest global full-service CRO and clinical research services provider. Overlaps with Caidya across clinical operations, data management, biometrics, and regulatory services, but with materially greater scale, broader therapeutic coverage, and a wider geographic footprint.

Direct peers

• ICON plc: Global full-service CRO offering Phase I-IV clinical trial management, biometrics, laboratory, and consulting services. Direct competitor for biotech and pharma sponsor awards, including in oncology, rare disease, and complex global trials where Caidya competes.
• Fortrea (formerly Labcorp Drug Development / Covance): Large global CRO spun out of Labcorp, providing Phase I-IV clinical trial services, central lab, and post-approval services. Direct overlap with Caidya's full-service CRO offering, and Caidya's COO previously led global project delivery at Fortrea.
• Syneos Health: Biopharmaceutical services organization providing clinical development and commercial services across Phase I-IV. Direct competitor for biotech sponsor awards and one of the closest comparables for a mid-to-large CRO serving small and mid-sized biotech.
• Parexel International: Global full-service CRO with deep biotech and biopharma client base, including complex therapeutic areas like oncology, rare disease, and cell/gene therapy. Closely comparable to Caidya in target customers and service scope.
• Medpace: Mid-sized, science-focused CRO with strong oncology, cardiometabolic, and rare disease expertise, known for operational efficiency. Comparable to Caidya in therapeutic specialization and biotech/biopharma sponsor focus, though it operates without a heavy China footprint.
• Worldwide Clinical Trials: Mid-sized global CRO with strong cardiovascular, metabolic, neuroscience, and rare disease expertise. Comparable to Caidya in scale, mid-biotech customer focus, and emphasis on complex global trials, including capabilities Caidya built through its predecessor Accovion lineage.
• Premier Research: Mid-sized CRO specializing in biotech and rare disease, pediatrics, oncology, and neurology. Comparable to Caidya in size, biotech customer focus, and emphasis on complex, smaller-population therapeutic programs.

Regional players

• Tigermed (Hangzhou Tigermed Consulting): Leading China-based full-service CRO with growing international footprint. Comparable to Caidya's cross-border China capability and a key competitor for China-inclusive clinical trials, particularly for sponsors seeking a regional rather than US/EU-anchored CRO.
• WuXi Clinical (WuXi AppTec subsidiary): China-rooted CRO providing Phase I-IV clinical development services with strong Asia-Pacific reach. Direct comparator for Caidya's China delivery model and a primary alternative for sponsors running trials with significant China site participation.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Facebookfacebook.com/Caidya
• LinkedInlinkedin.com/company/caidya
• Instagraminstagram.com/weare_caidya
• Xx.com/wearecaidya

Revenue estimate

Valuation estimate

Number of profiles

Profiles13 records

Subsidiaries5 records

Funding overview

Funding rounds2 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Caidya